| Attributes | Values |
|---|
| rdf:type
| |
| Description
| - Hematologic toxicity is reported as one of the most important problems connected with imatinib mesylate (IM) treatment in patients with chronic myelogenous leukemia (CML). Withholding the drug or application of growth factors is recommended in this situation. This study introduced a novel approach using intermittent dosage of IM in order to avoid prolonged interruptions in therapy, to allow spontaneous recovery in blood count and, simultaneously, to achieve intermittently therapeutic plasma drug levels. A retrospective analysis of intermittent therapy (iT) in 12 patients with CML is presented. All patients had intermediate-to-high prognostic scores. Two patients had history of autologous stem cell transplantation. Initial standard therapy with IM was indicated for resistance to interferon (eight subjects) and for accelerated phase in four cases (one of them cytogenetic) and lasted for 1 - 6 months. iT with 300 - 600 mg of IM 1 - 5 times a week was started after significant hematologic toxicity occurre
- Hematologic toxicity is reported as one of the most important problems connected with imatinib mesylate (IM) treatment in patients with chronic myelogenous leukemia (CML). Withholding the drug or application of growth factors is recommended in this situation. This study introduced a novel approach using intermittent dosage of IM in order to avoid prolonged interruptions in therapy, to allow spontaneous recovery in blood count and, simultaneously, to achieve intermittently therapeutic plasma drug levels. A retrospective analysis of intermittent therapy (iT) in 12 patients with CML is presented. All patients had intermediate-to-high prognostic scores. Two patients had history of autologous stem cell transplantation. Initial standard therapy with IM was indicated for resistance to interferon (eight subjects) and for accelerated phase in four cases (one of them cytogenetic) and lasted for 1 - 6 months. iT with 300 - 600 mg of IM 1 - 5 times a week was started after significant hematologic toxicity occurre (en)
- Hematologická toxicita je jedním z nejvýzamnějších problémů při léčbě chronické myeloidní leukemie pomocí imatinib mesylátu (IM). V této situaci je doporučováno vysazení léku nebo aplikace růstových faktorů. Tato studie uvádí nový přístup spočívající ve využití přerušovaného podávání IM ... (cs)
|
| Title
| - Intermittent dosage of imatinib mesylate in CML patients with a history of significant hematologic toxicity after standard dosing
- Přerušované dávkování imatinibu u CML pacientů se signifikantní hematologickou toxicitou po standardním dávkování (cs)
- Intermittent dosage of imatinib mesylate in CML patients with a history of significant hematologic toxicity after standard dosing (en)
|
| skos:prefLabel
| - Intermittent dosage of imatinib mesylate in CML patients with a history of significant hematologic toxicity after standard dosing
- Přerušované dávkování imatinibu u CML pacientů se signifikantní hematologickou toxicitou po standardním dávkování (cs)
- Intermittent dosage of imatinib mesylate in CML patients with a history of significant hematologic toxicity after standard dosing (en)
|
| skos:notation
| - RIV/61989592:15110/06:00003101!RIV09-MZ0-15110___
|
| http://linked.open...avai/riv/aktivita
| |
| http://linked.open...avai/riv/aktivity
| - P(GA301/04/1239), P(NR7870), Z(MSM6198959205)
|
| http://linked.open...iv/cisloPeriodika
| |
| http://linked.open...vai/riv/dodaniDat
| |
| http://linked.open...aciTvurceVysledku
| |
| http://linked.open.../riv/druhVysledku
| |
| http://linked.open...iv/duvernostUdaju
| |
| http://linked.open...titaPredkladatele
| |
| http://linked.open...dnocenehoVysledku
| |
| http://linked.open...ai/riv/idVysledku
| - RIV/61989592:15110/06:00003101
|
| http://linked.open...riv/jazykVysledku
| |
| http://linked.open.../riv/klicovaSlova
| - chronic myelogenous leukemia; CML; imatinib mesylate; intemittent therapy; Bcr/Abl (en)
|
| http://linked.open.../riv/klicoveSlovo
| |
| http://linked.open...odStatuVydavatele
| - GB - Spojené království Velké Británie a Severního Irska
|
| http://linked.open...ontrolniKodProRIV
| |
| http://linked.open...i/riv/nazevZdroje
| |
| http://linked.open...in/vavai/riv/obor
| |
| http://linked.open...ichTvurcuVysledku
| |
| http://linked.open...cetTvurcuVysledku
| |
| http://linked.open...vavai/riv/projekt
| |
| http://linked.open...UplatneniVysledku
| |
| http://linked.open...v/svazekPeriodika
| |
| http://linked.open...iv/tvurceVysledku
| - Faber, Edgar
- Indrák, Karel
- Jarošová, Marie
- Rožmanová, Šárka
- Holzerová, Milena
- Divoký, Vladimír
- Marešová, Ivana
- Veselovská, Jitka
- Egorin, Merrill J.
|
| http://linked.open...n/vavai/riv/zamer
| |
| issn
| |
| number of pages
| |
| http://localhost/t...ganizacniJednotka
| |
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)